LOGIN  |  REGISTER
Cue Biopharma
Astria Therapeutics

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

August 27, 2025 | Last Trade: US$26.35 0.44 -1.64

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in September:

  • 2025 Wells Fargo Healthcare Conference – Fireside chat on Wednesday, September 3, 2025 at 12:45 p.m. ET
  • Cantor Global Healthcare Conference 2025 – Fireside chat on Thursday, September 4, 2025 at 1:00 p.m. ET
  • H.C. Wainwright 27th Annual Global Investment Conference – Fireside chat on Tuesday, September 9, 2025 at 9:00 a.m. ET
  • Stifel 2025 Virtual Immunology & Inflammation Forum – Presentation on Monday, September 15, 2025 at 9:30 a.m. ET

To access the live webcasts or subsequent archived recordings of the fireside chats and presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.

RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.

RAPT Investor Contact:
Sylvia Wheeler
This email address is being protected from spambots. You need JavaScript enabled to view it. 

RAPT Media Contact:
Aljanae Reynolds
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page